Medulloblastoma Molecular Subtypes — Variants & evidence

Medulloblastoma Molecular Subtypes — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

6 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–6 of 6 evidence items (6 on this page mapped to a descendant entity) · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CTNNB1 D32Y1
(prognostic)	Medulloblastoma, WNT-Activated	Prognostic	C	Supports Better Outcome	3	submitted	EID9017 A retrospective study evaluated 72 pediatric medulloblastoma patients for CTNNB1 mutations (by direct sequencing), copy number alterations (by array-comparative genomic hybridization), and beta-cateni… (full text at CIViC) PMID 19197950 · Fattet et al., 2009 · Open in CIViC	civic
SNCAIP Tandem duplication1
(diagnostic)	Medulloblastoma, Non-WNT/Non-SHH, Group 4	Diagnostic	B	Supports Positive	3	submitted	EID11193 Analysis of somatic copy number alterations (SCNAs) in 1087 medulloblastoma tumours identified a recurrent tandem duplication of SNCAIP that was restricted to Group 4 medulloblastoma. SNCAIP duplicati… (full text at CIViC) PMID 22832581 · Northcott et al., 2012 · Open in CIViC	civic
TP53 Mutation4
(predisposing)	Medulloblastoma, SHH-Activated, TP53-MutantALIAS	Predisposing	B	Supports Predisposition	5	submitted	EID8346 This international, multicenter study analyzed patients with medulloblastoma (MB) from both retrospective and prospective cohorts in order to identify consensus MB predisposition genes. A total of 102… (full text at CIViC) PMID 29753700 · Waszak et al., 2018 · Open in CIViC	civic
(prognostic)	Medulloblastoma, SHH-Activated	Prognostic	B	Supports Poor Outcome	5	accepted	EID8347 In the childhood (≥4.3 years) SHH-MB subgroup, TP53 mutations (n=13) are associated with shorter progression-free survival (PFS) compared to the no mutation group (n=35) (HR, 3.47; 95% CI, 1.29 to 9.3… (full text at CIViC) PMID 28545823 · Schwalbe et al., 2017 · Open in CIViC	civic
(diagnostic)	Medulloblastoma, SHH-Activated, TP53-MutantALIAS

Data updated 23 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.